HealthCare Global Enterprises runs India's largest oncology-focused hospital network, with 25 centers across India and Kenya, delivering surgical, medical and radiation oncology, plus advanced therapies like CAR-T and bone marrow transplants. In Q1 FY27 it reported adjusted EBITDA of INR1,339 million, up 20% year on year, with margins improving to 19.4% from 18.2% in the prior year's first quarter. Mature centers consistently deliver 26-27% EBITDA margins, while blended company margin sits at 19.4%, revealing significant headroom as younger centers scale. The competitive structure is concentrated; HCG positions itself as the leading oncology platform, with 16 of its 25 centers achieving record quarterly revenues in Q1 FY27, and it is deliberately shedding low-margin institutional business to improve payor mix.
The economics persist because of clinical differentiation and high barriers to entry. HCG operates one of India's most modern MR-LINAC machines at its new North Bangalore facility, runs organ-specific surgical teams, and has built a referral destination for complex cancer care across the country. It onboarded ~20 oncologists in the last four to five months, and its 25-center network generates a large patient pool for analytics and AI. The capital intensity of building greenfield hospitals, along with multi-year clinician recruitment and insurance empanelment cycles, makes replication slow. Additionally, HCG's voluntary discontinuation of high-value, low-margin chemotherapy drugs (a 1.5% top-line hit) shows pricing discipline that strengthens the earnings quality over time.
The inflection is the capacity pipeline and the North Bangalore ramp. In Q1 FY27, HCG added 121 operational beds (61 South, 27 West, 26 East, 7 Kenya), and plans another 65 beds in FY27, followed by 520 beds across FY28-29 and 230 in FY30, with roughly 60% of this from brownfield expansions. North Bangalore, which commissioned its MR-LINAC in July 2026, saw 550+ new patient registrations and 300+ admissions in its first quarter; management expects monthly breakeven within the current financial year (FY27) and optimal utilization of 60-65% by its third to fourth year. By 18-24 months from now, likely mid-2028, the network should reflect the first wave of brownfield additions (Cuttack 75 beds, Ranchi 30, Vizag 50, Bhavnagar 20+) and one greenfield hospital (Whitefield) targeted for end of FY27/early FY28, positioning revenue growth at mid-teens with EBITDA margins moving toward 21-22% in the next two years, as guided on the Aug 2026 call.
Management's consistency is established. In Feb 2026 they had guided 15%+ revenue growth and 20% EBITDA CAGR; the 9M FY26 results showed 16% revenue growth and 20% EBITDA growth with an 18.3% margin. On the May 2026 call, they reaffirmed the 15% growth target and the 23-24% EBITDA margin aspiration over three to four years, and FY26 ended with revenue of INR2,545 crore (up 15%) and adjusted EBITDA margin at 18.5% (up 70 bps). They completed a INR425 crore rights issue to fund capacity and repaid INR170 crore of debt, reducing net debt-to-EBITDA to 1.4x from 2.2-2.3x. The Milann fertility sale signed in May 2026 is expected to close within Q1 FY27, sharpening oncology focus. New CFO and Head of IR have been appointed, and management has repeatedly delivered on capacity addition timelines, with North Bangalore starting operations at end of Q4 FY26 as committed.
The earnings path to 18-24 months is visible: mid-teens revenue growth, driven by volume (existing centers have ~60% revenue potential headroom) and 4-5% ARPP growth, combined with operating leverage taking adjusted EBITDA margin from 19.4% (Q1 FY27) to 21-22% by early FY29. For this to hold, North Bangalore must hit breakeven in FY27, brownfield beds must achieve targeted utilization, and payor mix must continue shifting toward non-institutional business (69% as of Q1 FY27, up from 67% a year earlier). The key falsifier is the North Bangalore ramp speed, which depends on insurance empanelments and clinician practice building; a delay would push out margin expansion. Additionally, price capping (CGHS headwind ~1.5% of revenue) and West cluster's declining institutional business (down >16% YoY in Q1 FY27) could cap revenue growth, but these are structural cleanup items rather than demand weakness, and the company's consistent execution against its guided capacity and margin milestones supports a high-confidence operating-leverage thesis.
companyname: HealthCare Global Enterprises Limited ticker: HCG sector: Healthcare – Oncology (Cancer Care) HealthCare Global Enterprises Limited (HCG) is India's largest cancer-focused hospital network. It operates 25 hospitals across 10 states and 19 cities, with over 2,500 beds, 38 LINACs (radiation therapy machines), 100+ operating theatres, and 400+ oncologists (AR FY25). The company was founded in 1989 as the Bangalore Institute of Oncology and has built its model around one disease: cance...
Read the full report →capex, margin expansion, management upgrade
FY27 revenue growth guided at 15% driven by capacity expansion and improved utilization
Guidance maintainedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for HealthCare Global Enterprises Limited and 4,900+ companies.
5-day free pass. No card required.